Skip to content
Clinical Trials – home

Universitaet Rostock

Verified siteinfo

Germany Schillingallee 35, Hansaviertel, 18057 Rostock, Germany

  • 3 trials recruiting
  • Acute myeloid leukaemia · Prostate cancer metastatic · Transitional cell carcinoma
  • Adults and children

About Specializations

Universitaet Rostock in Rostock, Germany specialises in clinical trials of conditions such as Acute myeloid leukaemia, Prostate cancer metastatic, Transitional cell carcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms Research at Universitaet Rostock

The department of Medizinische Klinik III für Hämatologie, Onkologie und Palliativmedizin concentrates on blood‑related cancers, seeking better therapies for both adult and pediatric patients.

  • Acute Myeloid Leukemia (AML)
  • Relapsed Acute Lymphoblastic Leukemia (ALL)
  • Optimization of chemotherapy dosing
  • Evaluation of novel agents such as L‑Annamycin
  • Assessment of bortezomib‑based induction regimens

Current studies aim to raise complete remission rates and define the most effective dosage schedules, offering new hope for patients with high‑risk or refractory disease at this European research site.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Schillingallee 35, Hansaviertel18057 RostockGermany
Recruiting now
3 trials
Conditions studied
3
Partner status
Verified site

More sites in RostockGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Annamycin
  • Sponsor:Moleculin Biotech Inc.
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.